2 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression Selinexor combined with Prednisone, Etoposide, and Lenalidomide - DLBCL | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 67 | 2022-10-01 | 2022-08-19 |
| Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) IBI110 plus sintilimab, IBI110 - DLBCL | Phase 1 | Unknown | Innovent Biologics (Suzhou) Co. Ltd. | 50 | 2021-09-27 | 2021-09-09 |
Recurrence (1)
Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Etoposide (1) · Lenalidomide (1) · Prednisone (1) · sintilimab (1)
Innovent Biologics (Suzhou) Co. Ltd. (1) · The Affiliated Hospital of Qingdao University (1)
China (2)